GIPR and obesity due to melanocortin 4 receptor deficiency: Whereas the related incretin hormone GLP-1 has found widespread therapeutic use, the complex nature of GIP biology has meant that proposals for agonism (7) or antagonism of the GIPr (8) for the treatment of diabetes and obesity have yet to lead to therapeutic applications.